文献速递神经肿瘤

复发性非典型脑膜瘤舒尼替尼治疗相关影像学显著反应致脑脊液鼻漏:病例报告

Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report.
PubMed 文献 · J Neurosurg · 2016-12-09

本文报告一例39岁女性复发性非典型脑膜瘤患者,经多次手术和放疗后肿瘤进展,接受舒尼替尼治疗后出现影像学显著反应,肿瘤体积明显缩小、脑干血管源性水肿减轻,但斜坡区肿瘤消退导致硬脑膜缺损并引发脑脊液鼻漏,需暂停舒尼替尼并行经蝶入路自体脂肪移植及带血管蒂鼻中隔黏膜瓣填塞修补,填塞后随访3个月无脑脊液漏复发,随后重启舒尼替尼治疗。

要点

  • 舒尼替尼治疗复发性非典型脑膜瘤可致影像学显著反应,肿瘤体积明显缩小。
  • 侵袭性颅底脑膜瘤影像学显著反应后可能出现硬脑膜缺损相关脑脊液鼻漏。
  • 经蝶入路自体脂肪联合带血管蒂鼻中隔黏膜瓣填塞可修补脑脊液漏,随访3个月无复发。

核心结论

  • 既往临床数据及本例影像学显著反应提示,舒尼替尼在常规策略已用尽的经仔细选择的复发性非典型脑膜瘤患者中具有前景性治疗潜力。
  • 尤其对影像学显著反应的更具侵袭性颅底病变,存在相关脑脊液鼻漏的潜在风险。

研究设计与样本

  • 病例报告:一例39岁女性复发性颅脑及脊髓脑膜瘤患者,既往11年间多次手术及放疗。
  • 右侧岩斜区脑膜瘤伴海绵窦及颈静脉孔延伸,4年内4次手术,组织学由最初WHO I级进展至第三次复发时WHO II级。
  • 后续复发再行3次立体定向放射外科治疗。

主要发现

  • 近期影像示肿瘤迅速增大,伴脑干受压及血管源性水肿所致进行性神经症状。
  • 开始舒尼替尼治疗后数周内出现影像学显著反应,肿瘤体积明显缩小、脑干血管源性水肿减轻。
  • 斜坡区肿瘤显著影像学反应同时出现由侵袭性颅底脑膜瘤消退所致硬脑膜缺损引起的脑脊液鼻漏,需暂停舒尼替尼。
  • 行手术探查及经蝶入路自体脂肪移植联合带血管蒂鼻中隔黏膜瓣填塞修补。
  • 填塞后随访3个月患者情况良好,无脑脊液漏复发证据,随后重启舒尼替尼。

临床怎么用

  • 作者指出,既往临床数据及本例影像学显著反应提示舒尼替尼在常规策略已用尽的经仔细选择的复发性非典型脑膜瘤患者中具有前景性治疗潜力。
  • 作者指出,尤其对影像学显著反应的更具侵袭性颅底病变,存在相关脑脊液鼻漏的潜在风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sunitinib is a multiple tyrosine kinase inhibitor with antiangiogenic, cytostatic, and antimigratory activity for meningiomas. A recent clinical trial of sunitinib for treatment of recurrent Grade II and III meningiomas suggested potential efficacy in this population, but only 2 patients exhibited significant radiographic response with tumor volume reduction. The authors illustrate another such case and discuss a complication related to this dramatic tumor volume reduction in aggressive skull base meningiomas. The authors describe the case of a 39-year-old woman who had undergone repeat surgical interventions and courses of radiotherapy over the previous 11 years for recurrent cranial and spinal meningiomas. Despite 4 operations over the course of 4 years on her right petroclival meningioma with cavernous sinus and jugular fossa extensions, she had progressive neurological deficits and tumor recurrences. The specimen histology progressed from WHO Grade I initially to Grade II at the time of the third recurrence. The lesion was then irradiated 3 times using stereotactic radiosurgery for further recurrences. More recently, the tumor size increased rapidly on imaging, in association with progressive neurological symptoms arising from brainstem compression and vasogenic edema. Institution of sunitinib therapy yielded a dramatic radiographic response, with marked reduction in the tumor volume and reduction of brainstem vasogenic edema within a few weeks of initiation of treatment. The significant radiographic response of tumor in the clival region was also associated with CSF rhinorrhea from a dural breach created by resolution of the invasive skull base meningioma, which necessitated withholding the sunitinib medication. To address the leak, the authors undertook surgical exploration and transsphenoidal packing using an autologous fat graft and a vascularized pedicled nasoseptal flap. The patient has done well during follow-up of 3 months after packing, with no evidence of recurrent CSF leak, and the medication was subsequently restarted. Prior clinical data and the dramatic radiographic response in this patient suggest that sunitinib holds promising therapeutic potential in carefully selected patients with recurrent atypical meningiomas where conventional strategies have been exhausted. There is a potential risk of associated CSF rhinorrhea, especially in more invasive skull base lesions showing dramatic radiographic response.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Raheja A, Colman H, Palmer CA, et al. Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report. J Neurosurg. 2016. PMID: 27935362. doi:10.3171/2016.9.JNS161629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。